Blog

Discover the latest biomarker-based methods and how they can be leveraged to add value to oncology trials.

ICON’s Data Management team provides advice and guidance on legacy conversion process and what you need to implement to remain compliant.

Medical device developers are emerging into the precision medicine market in a variety of therapeutic areas, including neurology, cardiology and infectious diseases.

As pharmaceuticals move from animal to first-in-human (FIH) clinical trials, establishing appropriate strategies to minimise risk in early phase clinical trials is necessary.

Successful clinical trial recruitment requires a thorough understanding of the target patient profile, and a key factor within this profile is patient motivation.

The US Food & Drug Administration (FDA) amended requirements for the acceptance of clinical data cllected outside the US to support medical device submissions.

The opportunity for blockchain in healthcare and clinical trials.

Late phase studies are ripe for digitalisation, although not always in the same ways as Phase II and III programs.

Learn how to use biostatistics using RMST in Oncological trials to improve clinical outcomes

NASH ranks among the world’s great emerging health threats

ICON has developed a lab logistics program to reduce costs

There is an increasing demand from sponsors for technology and data-driven solutions to improve site selection, study start- up and patient recruitment.

An insulin injector is significantly safer and easier to use, and therefore leads to fewer complications and better clinical outcomes.

The FDA issued a draft guidance on the Expanded Abbreviated 510(k) program, which describes an optional pathway for certain widely understood device types.

This is the first posting in a three-part series drawn from ICON’s webinar, “Evolving Best Practices for Working with Authors—Authorship and Beyond.”

Find out about the FDA's pathway to assist industry in expediting drug development.

Benefits include better, more personalised, treatment and improved clinical outcomes, with fewer clinic visits and greater independence for patients.

Emerging mHealth technologies are transforming patient care by integrating health data across the healthcare landscape.

Artificial intelligence (AI) technology, combined with big data, hold the potential to solve many key clinical trial challenges.

Recent approvals of CAR-T immuno-oncology therapies present a market opportunity estimated to grow nearly 50 percent annually over the next decade.